Name: Patent Litigation Strategy in The Post
Start: 2013-06-21T05:00

Why Fish

Diversity, Equity & Inclusion

Pro Bono & Social Responsibility

Legal Operations

Pricing

Legal Project Management

Knowledge Management

eDiscovery

Legal Technology Services

Trademark, Copyright & Media Litigation

Trade Secret Litigation

Appellate

Standard Essential Patents

Chancery & Corporate Governance

Post-Grant

Inter Partes Review

Post-Grant Review

Ex Parte Reexamination

Supplemental Examination

Patent

Patent Prosecution

Strategic Patent Counseling & Opinions

Patent Portfolio Management

Unitary Patent & Unified Patent Court

IP Licensing, Transactions & Agreements

Trademark & Copyright Counseling & Prosecution

Strategic Counseling, Registration & Opinions

Advertising & Marketing

Domain Names & Internet

TTAB Oppositions & Cancellations

Digital Millennium Copyright Act

Transactions & Agreements

Regulatory & Government Affairs

Communications & Spectrum Regulation

Drug & Medical Device Regulation

mHealth & Telemedicine

Privacy & Data Security

Industries

Electrical & Computer Technology

Artificial Intelligence

Digital Health

Digital Media & E-Commerce

Financial, Business & FinTech Services

Biotech & Diagnostics

Medical Devices

Pharmaceuticals

Academic Research & Medical Centers

Transportation, Aerospace & Defense

Post-Grant Annual Reports

Indranil Mukerji is moderating the Patent Litigation Strategy in The Post-AIA World panel at the NASABA convention on Friday, June 21.

Patent Litigation Strategy in The Post-AIA World

Association of Corporate Patent Counsel Summer Meeting 2025

The PREVAIL Act Is Back. Will It Prevail This Time?

Federal Circuit Reverses Injunction That Barred Clinical Trials in Jazz v. Avadel

Navigating Change at the USPTO

En Banc Federal Circuit Grants Google a New Trial in EcoFactor Case

John Squires Faces the Senate Judiciary Committee

Acting USPTO Director Stewart Issues First Decisions Under Interim Discretionary Denial Process

ITC Round-Up: Q1 2025

Can Clinical Trials Negate Patentability for Pharma Inventions?

PTAB Issues FAQs on Interim Process for Workload Management

Munich Appeals Court Reinforces Security-Centric FRAND Framework in SEP Dispute